✦ LIBER ✦

Hallucinations in narcolepsy with and without cataplexy: Contrasts with Parkinson’s disease

✍ Scribed by Smaranda Leu-Semenescu; Valerie Cochen De Cock; Valerie Dauriac Le Masson; Rachel Debs; Sophie Lavault; Emmanuel Roze; Marie Vidailhet; Isabelle Arnulf

Book ID: 116885075
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 193 KB
Volume: 12
Category: Article
ISSN: 1389-9457
DOI: 10.1016/j.sleep.2011.03.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Olfactory dysfunction in narcolepsy with

Olfactory dysfunction in narcolepsy with and without cataplexy

✍ Jitka Buskova; Jan Klaschka; Karel Sonka; Sona Nevsimalova 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Verbal memory in Parkinson's disease wit

Verbal memory in Parkinson's disease with and without depression: Comparisons and contrasts with Alzheimer's disease

✍ A.I. Tröster; J.A. Fields; A.M. Paolo; W.C. Koller 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Severe fatigue in narcolepsy with catapl

Severe fatigue in narcolepsy with cataplexy

✍ HAL A. DROOGLEEVER FORTUYN; ROLF FRONCZEK; MIRJAN SMITSHOEK; SEBASTIAAN OVEREEM; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

Cortical morphometry in narcolepsy with

Cortical morphometry in narcolepsy with cataplexy

✍ MARIE SCHAER; ROSITSA PORYAZOVA; SOPHIE SCHWARTZ; CLAUDIO L. BASSETTI; CHRISTIAN 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB

Development of Parkinson’s disease in pa

Development of Parkinson’s disease in patients with Narcolepsy

✍ Christine, Chadwick W.; Marks, William J.; Ostrem, Jill L. 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 140 KB

Effects of rivastigmine in patients with

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease

✍ David Burn; Murat Emre; Ian McKeith; Peter Paul De Deyn; Dag Aarsland; Chuanchie 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB 👁 1 views

## Abstract We aimed to determine prospectively whether rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, provided benefits in patients with and without visual hallucinations in a population with dementia associated with Parkinson's disease (PDD). This was a 24‐week doub